Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study

Philip J. Johnson, Shukui Qin, Joong Won Park, Ronnie T.P. Poon, Jean Luc Raoul, Philip A. Philip, Chih Hung Hsu, Tsung Hui Hu, Jeong Heo, Jianming Xu, Ligong Lu, Yee Chao, Eveline Boucher, Kwang Hyub Han, Seung Woon Paik, Jorge Robles-Aviña, Masatoshi Kudo, Lunan Yan, Abhasnee Sobhonslidsuk, Dmitry KomovThomas Decaens, Won Young Tak, Long Bin Jeng, David Liu, Rana Ezzeddine, Ian Walters, Ann Lii Cheng

Research output: Contribution to journal › Article › peer-review

598 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science